Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease

Roflumilast is an oral phosphodiesterase-4 selective inhibitor with anti-inflammatory action targeting the systemic inflammation associated with chronic obstructive pulmonary disease (COPD). Several studies have recently evaluated the clinical efficacy and safety of roflumilast in the treatment of COPD, showing its capacity in reducing exacerbations and hospital admissions in patients at risk of frequent and severe exacerbations despite conventional inhaled therapy with inhaled corticosteroids, long-acting beta-agonists, and long-acting muscarinic antagonist.[1,2